Market Introduction
Hematuria is a medical condition where presence of blood is found in the urine. Generally, urine does not contain RBC and hence this can result in serious issue that may also cause kidney stones, urinary tract infection and other inherited diseases.
Moreover, the high prevalence hematuria associated indications is expected to bolster the market growth during the forecast period. However, undiagnosed cases of associated indications limit the growth of the Europe hematuria treatment market.
A variety of patients have reported progressive acute kidney injury (AKI) at admission and during hospitalization and mild proteinuria symptoms for hematuria, which are associated with adverse clinical outcomes in inpatients with COVID 19. Proteinuria and hematuria are reported to have an even higher prevalence in COVID-19 than AKI. Retrospective studies in China have reported that proteinuria and hematuria are associated with COVID-19 and with higher mortality. In addition, according to the European Kidney Association (ERACODA) COVID19 database established in March 2020, approximately 25% of kidney transplant patients are diagnosed with coronavirus. Therefore, an increase in COVID-positive patients is expected to be more likely to be treated for kidney disease.
Market Overview and Dynamics
The Europe hematuria treatment market is projected to reach US$ 313.8 million by 2028 from US$ 270.5 million in 2021; it is anticipated to grow at a CAGR of 2.1% from 2021 to 2028. The patients across the region mostly prefer at-home care services. Wearable and portable medical devices hold major potential to improve treatment by allowing patients to continue with their daily activities along with the dialysis process. For instance, at-home dialysis offers greater flexibility with work and lifestyle schedules for patients. In addition, the overall procedure of home hemodialysis is much simplified as compared to traditional dialysis. Thus, wearable and implantable devices could provide patients the freedom to work and perform their daily activities during treatment. Such advanced therapeutic alternatives are likely to drive the Europe hematuria treatment market in years to come.
Key Market Segments
In terms of type, the macroscopic hematuria segment accounted for the largest share of the Europe hematuria treatment market in 2020. In terms of treatment, the drugs segment accounted for the largest share of the Europe hematuria treatment market in 2020. In terms of indication, the urinary tract infection segment accounted for the largest share of the Europe hematuria treatment market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the Europe hematuria treatment market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the hematuria treatment market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Boehringer Ingelheim International GmbH.
Reasons to Buy Report
EUROPE HEMATURIA TREATMENT MARKET SEGMENTATION
By Treatment
By Indication
By Type
By End User
By Country
Companies Mentioned
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 270.5 Million |
| Market Size by 2028 | US$ 313.8 Million |
| CAGR (2021 - 2028) | 2.1% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Treatment
|
| Regions and Countries Covered |
Europe
|
| Market leaders and key company profiles |
|
The Europe Hematuria Treatment Market is valued at US$ 270.5 Million in 2021, it is projected to reach US$ 313.8 Million by 2028.
As per our report Europe Hematuria Treatment Market, the market size is valued at US$ 270.5 Million in 2021, projecting it to reach US$ 313.8 Million by 2028. This translates to a CAGR of approximately 2.1% during the forecast period.
The Europe Hematuria Treatment Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Hematuria Treatment Market report:
The Europe Hematuria Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Hematuria Treatment Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Hematuria Treatment Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Hematuria Treatment Market
